---
figid: PMC6788940__nihms-1034181-f0002
figtitle: Targetable pathways in ESR1 mutant cells identified in preclinical studies
organisms:
- Homo sapiens
- unidentified
- Actitis hypoleucos
pmcid: PMC6788940
filename: nihms-1034181-f0002.jpg
figlink: pmc/articles/PMC6788940/figure/F2/
number: F2
caption: Targetable pathways in ESR1 mutant cells identified in preclinical studies.
  GFR signaling through IGF-1R activates the PI3K pathway, which is inhibited with
  GFR inhibitors or PI3K inhibitors. CDK2 and CDK7 phosphorylate and activate ER.
  NOTCH, HDACs, BET family proteins, ER coactivators, or ER itself are altered and
  implicated in resistance of ER mutant cancers. Immunotherapies targeting PD-1 are
  currently in breast cancer clinical trials. GFRs, growth factor receptors; EnR,
  endoplasmic reticulum; CoA, coactivator; HDAC, histone deacetylase; MHC, major histocompatibility
  complex; TCR, T cell receptor
papertitle: ESR1 Mutations in Breast Cancer.
reftext: Derek Dustin, et al. Cancer. ;125(21):3714-3728.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9817321
figid_alias: PMC6788940__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6788940__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6788940__nihms-1034181-f0002.html
  '@type': Dataset
  description: Targetable pathways in ESR1 mutant cells identified in preclinical
    studies. GFR signaling through IGF-1R activates the PI3K pathway, which is inhibited
    with GFR inhibitors or PI3K inhibitors. CDK2 and CDK7 phosphorylate and activate
    ER. NOTCH, HDACs, BET family proteins, ER coactivators, or ER itself are altered
    and implicated in resistance of ER mutant cancers. Immunotherapies targeting PD-1
    are currently in breast cancer clinical trials. GFRs, growth factor receptors;
    EnR, endoplasmic reticulum; CoA, coactivator; HDAC, histone deacetylase; MHC,
    major histocompatibility complex; TCR, T cell receptor
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ADA2
  - IGF1
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CD274
  - HLA-C
  - IGF1R
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - CDK2
  - EPHB2
  - MAPK1
  - MAPK3
  - NCOA3
  - CDK7
  - HDAC9
  - HDAC1
  - HDAC2
  - HDAC3
  - HDAC8
  - HDAC4
  - HDAC5
  - HDAC7
  - HDAC6
  - HDAC10
  - SIRT1
  - SIRT2
  - SIRT3
  - SIRT4
  - SIRT5
  - SIRT6
  - SIRT7
  - HDAC11
  - NOTCH1
  - NOTCH2
  - NOTCH3
  - NOTCH4
  - DNER
  - BHPI
  - RO4929097
  - 'Cytotoxic '
---
